Advertisement
UK markets open in 21 minutes
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,742.98
    +458.44 (+2.65%)
     
  • CRUDE OIL

    84.00
    +0.43 (+0.51%)
     
  • GOLD FUTURES

    2,351.60
    +9.10 (+0.39%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • Bitcoin GBP

    51,419.04
    +18.55 (+0.04%)
     
  • CMC Crypto 200

    1,391.08
    -5.45 (-0.39%)
     
  • NASDAQ Composite

    15,611.76
    -100.99 (-0.64%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?

Can Teva’s Fremanezumab Revert Chronic Migraine to Episodic?

As we saw in the previous part of this series, Teva presented new data on fremanezumab at the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco. It is one of Teva’s key pipeline drugs and is expected to be a key growth driver for the company. Teva’s specialty products pipeline is provided in the graph below.